In the present study, most of the assessed patients underwent not only the standard Brazilian tests but also additional series. This may have contributed to a lower percentage of negative results in our findings when compared to the literature, in which test data using only the standard series is used as the reference. After a thorough anamnesis, the outpatients are submitted to additional tests to guide the investigation of the disease etiology.

The performance of patch tests when there is clinical suspicion helps in the diagnosis of the etiology in most cases. In the presence of a negative test result, other causes of eczema should be considered; mainly ICD and AD, in addition to the less frequent non-eczematous differential diagnoses. Another relevant point to consider is the possibility of not having tested the substance causing the ACD. In the present study, most patients underwent additional testing, not just the Brazilian standard series, which contributed to a lower percentage of negative results when compared to the literature.

Financial support

None declared.

Authors’ contributions

Mellanie Starck: Collection, analysis and interpretation of data; critical review of the literature.
Nathalie Mie Suzuki: Drafting and editing of the manuscript; critical review of the manuscript.
Mariana de Figueiredo Silva Hafner: Design and planning of the study; drafting and editing of the manuscript; critical review of the manuscript.
Rosana Lazzarini: Approval of the final version of the manuscript; design and planning of the study; effective participation in research orientation.

Conflicts of interest

None declared.

References

1. Lazzarini R, Duarte I, Ferreira AL. Patch tests. An Bras Dermatol. 2013;88:879–88.
2. Warshaw EM, Zhang AJ, Belsito DV, Fowler JF Jr, Taylor JS, Maibach HI, et al. Patients with negative patch tests: retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016. J Am Acad Dermatol. 2019;80:1618–29.
3. Uter W, Aberer W, Armario-Hita JC, Fernandez-Vozmediano JM, Ayala F, Balato A, et al. Current patch test results with the European baseline series and extensions to it from the ‘European Surveillance System on Contact Allergy’ network, 2007-2008. Contact Dermatitis. 2012;67:9–19.
4. Rodrigues DF, Neves DR, Pinto JM, Alves MF, Fulgêncio AC. Results of patch-tests from Santa Casa de Belo Horizonte Dermatology Clinic, Belo Horizonte, Brazil, from 2003 to 2010. An Bras Dermatol. 2012;87:800–3.
5. Rodrigues DF, Goulart EM. Patch test results in children and adolescents. Study from the Santa Casa de Belo Horizonte Dermatology Clinic, Brazil, from 2003 to 2010. An Bras Dermatol. 2015;90:671–83.

Mellanie Starck a, Nathalie Mie Suzuki b, Mariana de Figueiredo Silva Hafner b, Rosana Lazzarini a

a Dermatology Clinic, Santa Casa de São Paulo, São Paulo, SP, Brazil
b Faculty of Medical Sciences, Santa Casa de São Paulo, São Paulo, SP, Brazil

* Corresponding author.
E-mail: nathalie.suzuki@gmail.com (N.M. Suzuki).
Received 16 July 2021; accepted 20 September 2021
Available online 6 September 2022
https://doi.org/10.1016/j.ajdb.2021.09.014
0365-0596/ © 2022 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Proteomic study of facial melasma*

Dear Editor,

Melasma is hypermelanosis that affects photoexposed areas, especially in adult women, with a significant impact on quality of life by affecting visible areas and being recurrent, despite treatments. Its pathophysiology is not yet fully understood, but it results from the interaction between exposure factors (e.g., solar radiation and sex hormones) and genetic predisposition. Several dermal stimuli have been identified in the maintenance of melanogenesis in melasma, including the activity of fibroblasts, endothelium and mast cells, which promote elastinization of collagen, structural damage to the basement membrane, the release of growth factors (e.g., sSCF, bFGF, NGF, HGF) and inflammatory mediators (e.g., ET1, IL1, VEGF, TGFB).1-3

This study aimed to explore differentially exposed proteins in melasma skin when compared to adjacent, unaffected, photoexposed skin.

A cross-sectional study was carried out involving 20 women with facial melasma, without specific treatments for 30 days. Two biopsies were performed (by the same researcher), one at the edge of facial melasma and another on unaffected skin, 2 cm away from the first, as previously standardized.1-3 The mechanical extraction of proteins was performed, followed by their enzymatic digestion and mass

* Study conducted at the Department of Dermatology and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil and Centro de Estudos de Venenos e Animais Peçonhentos, Universidade Estadual Paulista, Botucatu, SP, Brazil.
spectrometry. The project was approved by the institutional ethics committee (n. 1,411,931).

The samples were analyzed in duplicate in the nanoACQUITY-UPLC system coupled to a Xevo-Q-TOF-G2 mass spectrometer, and the results were processed with the ProteinLynx Global Server 3.03v software. The proteins were identified using the ion-counting algorithm, whose spectral patterns were searched in the Homo sapiens database, in the UniProt catalog (https://www.uniprot.org/).

All identified proteins with >95% similarity were included in the analysis. The intensities of the ion peaks were normalized, scaled and compared between topographies by a Bayesian algorithm (Monte Carlo method), which returns a value of p ≤ 0.05 for down-regulated proteins and ≥0.95 for up-regulated proteins, corrected by the Benjamini-Hochberg procedure.4

The main outcome of the study was the difference between the intensities of the neural peaks of the proteins (Melasma: M, Perilesional: P). The effect size was estimated by the ratio of these amounts between topographies (M/P). Proteins with an M/P ratio of ≤0.5 or ≥2.0 were considered in this study.

The identified proteins and their biological functions were diagrammed in a heat map and grouped using the cluster procedure (Ward method).

The mean age (standard deviation) of the patients was 42.8 (8.9) years old, 70% were phototypes III–IV and 25% worked in professions in which they were exposed to the sun. The age of melasma onset was 29.3 (7.5) years; 55% of the women reported a family history and 30% used contraceptives.

A total of 256 proteins were validated in the skin samples, and the 29 proteins differentially quantified between the topographies are shown in Table 1. The greatest discrepancies occurred for proteins HBD, EXPH5, KRT1, KRT9, REV3L (M/S > 4.00); and ACAP9, ADGB, CA1 (M/S < 0.33).

The main biological functions of these proteins are shown in Table 2. Fig. 1 represents the interaction between the 29 proteins and their biological functions. Proteins ACTG1, ALB, SERPINA1, HBD, ALDOA, and FGG showed to be co-participants in different biological processes, such as oxygen consumption, glycolysis, gluconeogenesis, and cell transport, suggesting an increase in the metabolic activity of the skin with melasma.

Exophyllin-5 (EXPH5) is linked to intracellular vesicle transport. It was up-regulated (M/S = 8.94) in melasma, which may be due to the intense epidermal transfer of melanosomes.1 Thirteen of the proteins differentially identified in melasma have been linked to intracellular transport phenomena, which comprise a series of processes ranging from endocytosis to autophagy and several forms of exocytosis. As autophagy and senescence are melanogenesis-related phenomena, characterization of transport vesicles in the melasma epithelium may prove to be important in the pathophysiology of melasma.6,7

Cytokeratins (such as KRT1) are structural constituents of keratinocytes induced in response to oxidative stress. They were identified in greater proportion in melasma (M/S > 4.10). Hemoglobin-δ (but not the other subunits) showed a high ratio (M/S = 33.12) in melasma, and, in addition to oxygen transport, its non-erythrocytic expression occurs in situations of cell stress.7 Likewise, up-regulation of alpha 1-antitrypsin (SERPINA1) and actin gamma-1 (ACTG1) is also seen in tissue stress conditions.6,9 The higher expressions of HBD, ACTG1, SERPINA1, and KRT1 in melasma may be due to oxidative stress sustained by mast cell tryptase activity and the secretory phenotype of upper dermis fibroblasts.5,6

Carbonic anhydrase (CA1) acidifies the extracellular environment of the dermis, favoring the repair process, being down-regulated (M/S < 0.33) in melasma.10 The senescence of dermal fibroblasts, associated with the activity of MMP1 and MMP9, promotes a pro-inflammatory microenvironment with degradation of the extracellular matrix and the basement membrane zone, the repair deficit of which may be a factor in the maintenance of melanogenesis.5,6

Androglubin (ADGB) has a cysteine-endopeptidase regulatory function, being identified in a lower ratio (M/S < 0.33) in melasma. Endopeptidases participate in the degradation of melanosomes in the epidermis, notably reduced in melasma. The alpha-kinase anchor proteins (ANCHOR9, ANCHOR13) and the z-catalytic subunit of DNA polymerase (REV3L) showed an imbalance in the skin with melasma. They are important in the regulation of protein kinase-A and the p38-MAP kinase pathway, involved in the activation of the CREB protein, which leads to the expression of MTIF, a promoter of melanogenesis.7

Aldolase-A (ALDOA) has a glycolytic function and is associated with the activity of mast cells, which, in the superficial dermis, promote changes in the basement membrane, solar elastosis, and endothelial dilation, reinforcing the idea that stimuli originating in the dermis play a central role in the melanogenesis of melasma.6

Fibrinogen-γ (FFG) is an extracellular matrix protein, and interacts in several biological functions, including fibrinolysis, fibrinogen activation and activation of the ERK pathway, a promoter of melanogenesis.

The main limitations of the study are related to transmembrane, serum and lipid-conjugated proteins, which are not identified by the method. However, it consistently points to a number of proteins with a pathophysiological role and potential therapeutic manipulation of which should be explored in specific assays.

In conclusion, the study identified 29 differentially regulated proteins in melasma, involved in energy metabolism, cell transport phenomena, regulation of melanogenesis pathways, hemostasis/coagulation, repair/healing, and response to oxidative stress. This supports the research of therapeutic strategies aimed at the identified proteins and their functions and shows that melasma does not depend exclusively on the hyperfunction of melanocytes but also on functional alterations involving the epidermal melanin unit, basement membrane zone and upper dermis.

Financial support

FUNADERSP (048/2016).

Authors' contributions

Luiza Vasconcelos Schaefer: Design and planning of the study; drafting and editing of the manuscript; collection,
Table 1  Proteins and isoforms identified in samples of facial melasma (M) and adjacent photoexposed (P) skin (n = 40) with the difference between the groups (p ≤ 0.05 or ≥0.95) and M/P ratio ≥2.0 or ≤0.5.

| Protein code | Protein | PLGS score | Melasma | Perilesional | Log2 M/P (sd) | M/P ratio | p-Value |
|--------------|---------|------------|---------|--------------|---------------|-----------|---------|
| P1 | Actin Alpha Skeletal Muscle ACTA1 | 958.81 | 1.34 (0.04) | 0.66 (0.04) | 1.04 (0.07) | 2.05 | 1.00 |
| P2 | Actin Cytoplasmic 2 ACTG1 | 1164.96 | 1.40 (0.06) | 0.60 (0.06) | 1.23 (0.11) | 2.34 | 1.00 |
| P3 | Actin Cytoplasmic 2 ACTG1 | 1164.96 | 1.40 (0.07) | 0.60 (0.07) | 1.24 (0.12) | 2.36 | 1.00 |
| P4 | A-Kinase Anchor Protein 13 AKAP13 | 87.85 | 1.53 (0.40) | 0.47 (0.40) | 1.96 (1.03) | 3.90 | 0.97 |
| P5 | Albumin isoform CRA k ALB | 542.99 | 0.62 (0.05) | 1.38 (0.05) | −1.14 (0.08) | 0.45 | 0.00 |
| P6 | Alpha-1-antitrypsin SERPINA1 | 1092.60 | 1.33 (0.13) | 0.67 (0.13) | 1.00 (0.21) | 2.00 | 1.00 |
| P7 | Androglobin ADGB | 69.19 | 0.48 (0.21) | 1.52 (0.21) | −1.69 (0.40) | 0.31 | 0.05 |
| P8 | Annexin ANXA2 | 117.73 | 1.33 (0.25) | 0.67 (0.25) | 1.01 (0.41) | 2.01 | 0.95 |
| P9 | Beta-actin-like protein 2 ACTBL2 | 101.00 | 1.43 (0.07) | 0.57 (0.07) | 1.34 (0.12) | 2.53 | 1.00 |
| P10 | Betatric-like protein 2 ACTBL2 | 53.81 | 1.57 (0.17) | 0.43 (0.17) | 1.90 (0.40) | 3.74 | 1.00 |
| P11 | Carbonic Anhydrase 1 CA1 | 1112.39 | 0.39 (0.17) | 1.61 (0.17) | −2.09 (0.45) | 0.23 | 0.00 |
| P12 | Ceruloplasmin CP | 76.55 | 1.40 (0.17) | 0.60 (0.17) | 1.23 (0.30) | 2.34 | 1.00 |
| P13 | DNA polymerase zeta catalytic subunit REV3L | 73.85 | 1.58 (0.34) | 0.42 (0.34) | 2.03 (0.86) | 4.10 | 0.95 |
| P14 | Exophilin-5 EXPH5 | 40.12 | 1.79 (0.12) | 0.21 (0.12) | 3.16 (0.48) | 8.94 | 1.00 |
| P15 | Fibrinogen Gamma chain FGG | 211.06 | 1.33 (0.16) | 0.67 (0.16) | 1.01 (0.25) | 2.01 | 1.00 |
Table 1 (Continued)

| Protein code | Protein                                                                 | PLGS score | Melasma (Log2 M/P (sd)) | Perilesional (Log2 M/P (sd)) | Log2 M/P (sd) | M/P ratio | p-Value^a |
|--------------|-------------------------------------------------------------------------|------------|-------------------------|-----------------------------|---------------|-----------|-----------|
| P16          | Fibrinogen Gamma chain FGG                                             | 211.06     | 1.34 (0.14)             | 0.66 (0.14)                 | 1.04 (0.24)   | 2.05      | 1.00      |
|              | Fructose-bisphosphate Aldolase A ALDOA                                 | 153.06     | 1.46 (0.07)             | 0.54 (0.07)                 | 1.43 (0.14)   | 2.69      | 1.00      |
|              | Fructose-bisphosphate aldolase A ALDOA                                 | 296.85     | 1.45 (0.07)             | 0.55 (0.07)                 | 1.41 (0.13)   | 2.66      | 1.00      |
|              | Fructose-bisphosphate aldolase ALDOA                                   | 295.30     | 1.46 (0.10)             | 0.54 (0.10)                 | 1.43 (0.17)   | 2.69      | 1.00      |
|              | Fructose-bisphosphate aldolase ALDOA                                   | 295.30     | 1.47 (0.08)             | 0.53 (0.08)                 | 1.46 (0.14)   | 2.75      | 1.00      |
| P17          | G Patch domain-containing protein 1 GPATCH1                            | 95.48      | 1.37 (0.14)             | 0.63 (0.14)                 | 1.13 (0.25)   | 2.18      | 1.00      |
|              | G patch domain-containing protein 1 GPATCH1                            | 88.85      | 1.60 (0.28)             | 0.40 (0.28)                 | 2.15 (0.66)   | 4.44      | 1.00      |
| P18          | Heat shock protein 75 kDa mitochondrial TRAP1                          | 124.78     | 1.43 (0.13)             | 0.57 (0.13)                 | 1.34 (0.24)   | 2.53      | 1.00      |
| P19          | Hemoglobin subunit alpha HBA1                                         | 8552.23    | 1.57 (0.02)             | 0.43 (0.02)                 | 1.88 (0.04)   | 3.67      | 1.00      |
| P20          | Hemoglobin subunit beta HBB                                            | 91.85      | 0.65 (0.05)             | 1.35 (0.05)                 | −1.07 (0.08)  | 0.48      | 0.00      |
| P21          | Hemoglobin subunit delta HBD                                           | 42.06      | 1.94 (0.02)             | 0.06 (0.02)                 | 5.05 (0.31)   | 33.12     | 1.00      |
| P22          | Keratin type I cytoskeletal 9 KRT9                                     | 340.12     | 1.61 (0.13)             | 0.39 (0.13)                 | 2.05 (0.27)   | 4.14      | 1.00      |
| P23          | Keratin type II cytoskeletal 1 KRT1                                    | 55.74      | 1.62 (0.06)             | 0.38 (0.06)                 | 2.08 (0.14)   | 4.22      | 1.00      |
| P24          | POTE ankyrin domain family member F POTEF                              | 101.00     | 1.47 (0.07)             | 0.53 (0.07)                 | 1.49 (0.14)   | 2.80      | 1.00      |
| P25          | Putative beta-actin-like protein 3 POTEKP                              | 101.00     | 1.47 (0.09)             | 0.53 (0.09)                 | 1.47 (0.16)   | 2.77      | 1.00      |
| P26          | RNA-binding protein 25 RBM25                                           | 29.17      | 1.57 (0.12)             | 0.43 (0.12)                 | 1.86 (0.25)   | 3.63      | 1.00      |
| P27          | Splicing Regulatory glutamine/Lysine-rich protein 1 SREK1              | 79.89      | 1.41 (0.26)             | 0.59 (0.26)                 | 1.28 (0.48)   | 2.44      | 1.00      |
| P28          | Tetra-tricopeptide repeat protein 37 TTC37                             | 443.53     | 1.45 (0.21)             | 0.55 (0.21)                 | 1.44 (0.42)   | 2.72      | 1.00      |
|              | Tetra-tricopeptide repeat protein 37 TTC37                             | 449.05     | 1.46 (0.18)             | 0.54 (0.18)                 | 1.47 (0.36)   | 2.77      | 1.00      |
| P29          | Triosephosphate isomerase TP1                                         | 475.34     | 1.39 (0.25)             | 0.61 (0.25)                 | 1.23 (0.41)   | 2.34      | 0.97      |
|              | Triosephosphate isomerase TP1                                         | 475.34     | 1.41 (0.22)             | 0.59 (0.22)                 | 1.28 (0.40)   | 2.44      | 0.97      |
|              | Triosephosphate isomerase TP1                                         | 576.90     | 1.43 (0.19)             | 0.57 (0.19)                 | 1.34 (0.37)   | 2.53      | 1.00      |

^a p-Value corrected by false discovery rate.
**Table 2**  Main functional pathways associated with the 29 proteins identified as differentials between melasma and perilesional skin.

| Functions                                           | Involved proteins | n (%) | FDR<sup>a</sup> |
|-----------------------------------------------------|-------------------|-------|-----------------|
| 1. Canonical glycolysis                             | p16, p29          | 2 (7) | <0.0001         |
| 2. Gluconeogenesis                                  | p16, p29          | 2 (7) | <0.0001         |
| 3. Fibrinolysis                                     | p8, p15, p23      | 2 (10)| <0.0001         |
| 4. Platelet degranulation                           | p2, p5, p6, p15,  | 5 (17)| <0.0001         |
|                                                     | p16               |       |                 |
| 5. Regulation of body fluids                        | p2, p5, p6, p8,   | 8 (28)| <0.0001         |
|                                                     | p15, p16, p21,    |       |                 |
|                                                     | p22, p23          |       |                 |
| 6. Oxygen transport                                 | p7, p19, p20, p21 | 4 (14)| <0.0001         |
| 7. Vesicle-mediated transport                       | p2, p5, p6, p10,  | 9 (31)| <0.0001         |
|                                                     | p14, p15, p16,    |       |                 |
|                                                     | p19, p20          |       |                 |
| 8. Platelet activation                              | p5, p6, p15, p16  | 4 (14)| <0.0001         |
| 9. Positive regulation of cell adhesion            | p15               | 1 (3) | 0.0001          |
| 10. Hemostasis                                      | p2, p5, p6, p15,  | 6 (20)| 0.0001          |
|                                                     | p16, p21          |       |                 |
| 11. Platelet aggregation                            | p2, p15           | 2 (7) | 0.0002          |
| 12. Plasminogen activation                          | p15               | 1 (3) | 0.0003          |
| 13. Single-organism transport                       | p2, p5, p6, p7, p8,p10, p11, p12, p14, p15, p16, p19, p20, p21 | 14 (48) | 0.0004          |
| 14. Blood clotting                                  | p2, p5, p6, p15,  | 6 (21)| 0.0008          |
|                                                     | p16, p21          |       |                 |
| 15. Error-prone translesion synthesis               | p13               | 1 (3) | 0.0010          |
| 16. Protein activation cascade                      | p15, p23          | 2 (7) | 0.0014          |
| 17. Retinal homeostasis                             | p2, p5, p23, p24  | 4 (14)| 0.0015          |
| 18. Down-regulation of trauma response              | p8, p10, p15      | 3 (10)| 0.0015          |
| 19. Up-regulation of exocytosis                     | p14, p15          | 2 (7) | 0.0016          |
| 20. Regulation of exocytosis                        | p10, p14, p15     | 3 (10)| 0.0017          |
| 21. Down-regulation of endothelial cell             | p15               | 1 (3) | 0.0022          |
| apoptosis process                                   |                   |       |                 |
| 22. Blood clotting, fibrin clot formation           | p15               | 1 (3) | 0.0024          |
| 23. Down-regulation of the extrinsic apoptosis      | p15               | 1 (3) | 0.0024          |
| signaling pathway through the receptor              |                   |       |                 |
| death domain                                        |                   |       |                 |
| 24. Transport                                       | p2, p4, p5, p6, p7,p10, p11, p12, p15, p16, p19, p20, p21 | 13 (45) | 0.0029          |
| 25. Monocarboxylic Acid Metabolic Process           | p5, p16, p29      | 3 (10)| 0.0030          |
| 26. Regulation of adhesion-dependent cell           | p15               | 1 (3) | 0.0033          |
| spread                                              |                   |       |                 |
| 27. Wound healing                                   | p2, p5, p6, p15,  | 6 (20)| 0.0035          |
|                                                     | p16, p21          |       |                 |
| 28. Bicarbonate transport                           | p11, p19, p20     | 3 (10)| 0.0044          |
| 29. Up-regulation of vasoconstriction               | p15               | 1 (3) | 0.0044          |
| 30. Response to calcium ion                         | p2                | 1 (3) | 0.0075          |
| 31. Regulation of transport by vesicles             | p8, p10, p14, p15 | 4 (14)| 0.0083          |
| 32. Secretion                                       | p5, p6, p8, p15,  | 5 (17)| 0.0092          |
|                                                     | p16               |       |                 |
| 33. Down-regulation by external stimuli             | p8, p10, p15      | 3 (10)| 0.0098          |
| 34. Response to stress                              | p2, p5, p6, p13,  | 9 (31)| 0.0100          |
|                                                     | p16, p19, p20,    |       |                 |
|                                                     | p21, p23          |       |                 |

<sup>a</sup> False discovery rate estimated according to the number of proteins expected for the function.
Figure 1  Heat map and dendrograms between identified proteins (rows) and biological functions (columns). Green highlights: grouping of proteins with a similar pattern of occurrence according to the functions they perform; and in red: the functions with a similar expression pattern, according to the indicated proteins.

analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature.

Leticia Gomes de Pontes: Collection, analysis, and interpretation of data.

Nayara Rodrigues Vieira Cavassan: Collection, analysis, and interpretation of data.

Lucilene Delazari dos Santos: Critical review of the literature; critical review of the manuscript; collection, analysis, and interpretation of data.

Hélio Amante Miot: Critical review of the literature; critical review of the manuscript; statistical analysis; approval of the final version of the manuscript; design and planning of the study.

Conflicts of interest

None declared.

References

1. Esposito ACC, Brianzei G, Souza NP, Miot LDB, Miot HA. Exploratory study of epidermis, basement membrane zone, upper dermis alterations and wnt pathway activation in melasma compared to adjacent and retroauricular skin. Ann Dermatol. 2020;32:101–8.
2. Lee AY. Recent progress in melasma pathogenesis. Pigment Cell Melanoma Res. 2015;28:648–60.
3. Esposito ACC, Brianzei G, Souza NP, Miot LDB, Marques MEA, Miot HA. Exploring pathways for sustained melanogenesis in facial melasma: an immunofluorescence study. Int J Cosmet Sci. 2018;40:420–4.
4. Knight JM, Ivanov I, Dougherty ER. MCMC implementation of the optimal Bayesian classifier for non-Gaussian models: model-based RNA-Seq classification. BMC Bioinformatics. 2014;15:401.
5. Esposito ACC, Souza NP, Miot LDB, Miot HA. Deficit in autophagy: a possible mechanism involved in melanocyte hyperfunction in melasma. Indian J Dermatol Venerol Leprol. 2021;1:1–3.
6. Kim M, Kim SM, Kwon S, Park TJ, Kang HY. Senescent fibroblasts in melasma pathophysiology. Exp Dermatol. 2019;28:719–22.
7. Saha D, Patgaonkar M, Shroff A, Ayyar K, Bashir T, Reddy KV. Hemoglobin expression in nonerythroid cells: novel or ubiquitous? Int J Inflamm. 2014;2014:803237.
8. Reiss MJ, Han YP, Garner WL. Alpha1-antichymotrypsin activity correlates with and may modulate matrix metalloproteinase-9 in human acute wounds. Wound Repair Regen. 2009;17:418–26.
9. Dong X, Han Y, Sun Z, Xu J. Actin Gamma 1, a new skin cancer pathogenic gene, identified by the biological feature-based classification. J Cell Biochem. 2018;119:1406–19.
10. Barker H, Aaltonen M, Pan P, Vähätupa M, Kalpiainen P, May U, et al. Role of carbonic anhydrases in skin wound healing. Exp Mol Med. 2017;49:e334.
Thin cutaneous melanoma: immunohistochemical expression of endoglin, VEGF-C and nestin

Dear Editor,

The incidence of melanoma is increasing worldwide, and even small, thin tumors can metastasize. Tumor progression includes proliferation, neovascularization, and lymphangiogenesis, and many mediators are important in this pathogenesis. Nestin (important in proliferation), endoglin (important in neovascularization), and VEGF-C (important in lymphangiogenesis) have already been described in cutaneous melanoma in general; but with little emphasis on thin melanomas.

We describe the clinical data of thin melanomas patients with and without metastases and the immunohistochemical expression of nestin, endoglin, and VEGF-C. The project was approved by the Research Ethics Committee of the institution (Counsel number: 332,405).

A case-control study was carried out with 85 patients: 20 patients in the study group and 65 in the control group. Patients in the study group were included when they had melanoma metastasis from a thin primary skin lesion (up to 1 mm thick). Controls were patients with thin melanoma but without metastasis. Data were collected regarding sex, age, topography, and histopathological subtype of the tumor.

Of the 85 patients, 37 expressed markers (seven in the study group and 30 in the control group). In the study group, three immunohistochemistry reactions were performed for each marker for each patient. In the control group, two reactions were performed for each marker for each patient, aiming at the statistical analysis of data in clusters. Nestin (ABCAM®), Endoglin (CD105; NOVO CASTRA®) and VEGF-C (IN VITRO GEN®) antibodies were used in the standard immunoperoxidase technique. The chromogenic substance was 3-Amino-9-Ethylcarbazole (AEC), as previously used in a prior study of melanoma.

For endoglin, the lesion hot spots were determined in ×10 magnification fields. Moderate to strong immunohistochemical reactions were considered positive. Up to four hot spots were photographed per slide with ×40 magnification objective. Subsequently, we counted the number of microvessels in each lesion. Areas of fibrosis were avoided, as they could correspond to repair neovascularization instead of neovascularization of the lesion.

To evaluate the differences among the immunohistochemical markers, an analysis based on the Generalized Estimating Equations (GEE) method was used. This technique takes into account the effect of data in clusters, in which a given patient can contribute with a greater number of observations than another. Thus, an adjustment is made for the correlated measures obtained from the same individual. According to the assumptions of data distribution, binding functions per identity (Gaussian), log and Poisson were used.

Regarding the statistical analysis, the quantitative data were described by means and standard error and the categorical variables by counts and percentages. Initial comparisons between groups were performed using Student’s t test or Fisher’s exact test. The level of significance was set at α = 0.05; data were entered into an Excel spreadsheet and analyzed using the IBM-SPSS program, version 22.0.

Most patients in the study group were male (75%), whereas, in the control group, 47% of the patients were male. This difference was statistically significant (p = 0.041). The mean age in the study group was 52 years and in the control group, 55 years. In both groups, the most frequent topographic location of the primary melanoma was the trunk. Also in both groups, the most frequent histopathological subtype was superficial spreading melanoma. These data showed no statistical difference (Table 1).

The immunohistochemical reactions of the markers are shown in Fig. 1 (A: Nestin, B: Nestin, C: Endoglin, D: Endoglin, E: VEGF-C, F: VEGF-C).

An immunohistochemical reaction was considered positive for endoglin when moderate to strong. In the study group, the mean number of identified vascular structures was 11.47, with a standard error of 1.27. In the control group, it was 9.22, with a standard error of 0.59. This non-significant difference reached a p-value of 0.088. Nestin and VEGF-C showed no differences between the groups.

The male sex is already known to have a worse prognosis among melanoma patients. In this study, patients with thin melanoma and metastases were significantly more often male than female.